Myeloablative Allo-SCT
Conditions
Keywords
Haematopoietic stem cell transplantation, Malignant hemopathy, Artificial nutrition
Brief summary
Myeloablative allogeneic hematopoetic stem cell transplantation (AHSCT) are prone to frequent secondary malnutrition to metabolic and digestive troubles due to conditioning regimen, treatments (antibiotics, immunosuppressive therapy…) and graft complications (graft versus host disease). In the absence of appropriate nutritional support, myeloablative conditioning lead to a rapid serious denutrition. But, it is known as negative independent prognostic factor of overall survival of patients who presented malignant hemopathy treated by high-dose chemotherapy or AHSCT. Furthermore, it increases hospitalisation delay and decreases quality of life. In AHSCT with myeloablative conditioning, introduction of nutritional support is recommended. However, type of nutritional support remains not clearly defined. Parenteral nutrition is user but favour infections and secondary effects potentially decrease by intravenous glutamine. Few previous studies with low number of patients, mainly retrospective or combining allo-and auto HSCT had shown feasibility, acceptable tolerance and low cost of enteral nutrition (EN). A recent prospective no-randomized study in 45 adults patients who had undergone AHSCT with myeloablative conditioning find a significant decrease of day-100 mortality (5% vs 30%), of infection mortality, of median duration of parenteral nutrition (PN) and prevalence of GvH (Graft versus Host Disease) grade III-IV in EN (enteral nutrition) group. These results had to be confirmed by a randomized study. As EN is 4 to 5 more cheaply than PN, besides mortality/morbidity stakes for the patient, this study could have potential economic interest.
Detailed description
EN (enteral nutrition) or PN (parenteral nutrition) artificial nutrition will be launched at D1-D2 of the transplantation (D0 being the day of the transplantation),without taking into account the oral intake. This helps in particular to launch the EN after the stage of significant digestive problems related to the conditioning and before the mucositis appearance. EN group: According to the HAS and SFNEP (Societe francophone nutrition clinique) recommendations and the good practice rules, a polyurethane or silicone NGT(Naso gastric tube), 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months. PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments.
Interventions
DRUGEnteral nutrition alanyl-glutamin, Dipeptiven
Enteral nutrition versus parenteral nutrition
Sponsors
Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
Société Francophone Nutrition Clinique et Métabolisme
Laboratoires NUTRICIA
University Hospital, Clermont-Ferrand
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Age between 18 and 65 years * Men and women * Patients undergoing myeloablative allo-SCT * Allo-SCT genoidentical or phenoidentical 10/10 * Patients affiliated with a social security organisation * Patients having signed the informed consent
Exclusion criteria
* Status of tumour progression at the moment of the allo-SCT * Artificial nutrition begun before the inclusion * Inability to understand the protocol (linguistic barrier, cognitive difficulties) * Contraindication or associated pathology that does not allow to carry out EN or PN according to the protocol * Medical history of progressive psychiatric illness * Medical history of another progressive cancer or occurrence in the 5 previous years * Presence of a simultaneous serious and uncontrolled disease such as severe cardiac, renal, hepatic or respiratory failure or severe sepsis * Previous allo-SCT * Participation in another clinical trial studying an allograft procedure, and applying modalities that are not available in routine practice (including innovative immunosuppression and graft or conditioning regimens not considered as myeloablative)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality related to the transplant | at day 100 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival and disease free survival | 12 months after AHSCT (hematopoietic stem cell transplantation) | — |
| Evolution of nutritional state | 12 months after AHSCT | All patients will received, whatever treatment arm, intravenous alanyl-glutamin, Dipeptiven which have AMM. |
| Occurrence of post-transplant complications targeting acute GVH, mucite and infections | 12 months after AHSCT (hematopoietic stem cell transplantation) | — |
| Engraftment rates | Day30, Day60, Day90 and Day180 | — |
| quality of life assessment | Day7, Day90, Day180 and Day360 | — |
| Tolerance of nutritional support mainly on digestive and hepatobiliary disorders | 12 months after AHSCT | All patients will received, whatever treatment arm, intravenous alanyl-glutamin, Dipeptiven which have AMM. |
Countries
France
Contacts
Primary ContactPatrick LACARIN
Outcome results
None listed